Reuters logo
1 年前
BRIEF-Tracon Pharmaceuticals announces positive results from TRC105 and TRC102 clinical trials
2016年6月6日 / 中午12点22分 / 1 年前

BRIEF-Tracon Pharmaceuticals announces positive results from TRC105 and TRC102 clinical trials

2 分钟阅读

June 6 (Reuters) - Tracon Pharmaceuticals Inc :

* Reported positive results from three separate clinical trials evaluating two clinical stage product candidates, TRC105 and TRC102

* Median pfs greater than 12 months with continued durable complete responses observed in angiosarcoma patients treated with trc105 and votrient

* Partial responses seen in solid tumor patients treated with trc102 and temodar

* On track to initiate randomized phase 3 study of trc105 with votrient in patients with angiosarcoma later this year at sites in u.s., europe

* Combination of trc105 and avastin was well-tolerated with no apparent increase in frequency or severity of adverse events

* Data from randomized phase 2 trial comparing treatment with combination of trc105 and avastin expected by end of 2016

* Tracon pharmaceuticals announces positive results from trc105 and trc102 clinical trials at american society of clinical oncology (asco) 2016 annual meeting Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below